New subcutaneous formulation of Celltrion Healthcares CTP13 biosimilar infliximab shows positive Phase 1 results for the treatment of IBD in data presented at UEG Week Barcelona 2019

Results from a multicentre openlabel randomised Phase 1 pivotal study showed that the subcutaneous SC formulation of CTP13 biosimilar infliximab was noninferior to intravenous IV formulation of CTP13 in terms of pharmacokinetics in inflammatory bowel disea...